Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation.
about
Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies.Towards a rational design of solid drug nanoparticles with optimised pharmacological properties.Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling.Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.Therapeutic surfactant-stripped frozen micelles.Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents.Role of polymer-drug conjugates in organ-specific delivery systems.Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics.Nanoformulation and encapsulation approaches for poorly water-soluble drug nanoparticles.Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers.Hyperbranched polydendrons: a new nanomaterials platform with tuneable permeation through model gut epithelium.Advances in nanomedicine drug delivery applications for HIV therapy.Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices.Long-acting injectable atovaquone nanomedicines for malaria prophylaxis.The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery.Dual-stimuli responsive injectable microgel/solid drug nanoparticle nanocomposites for release of poorly soluble drugs.Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems.Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system.Harnessing nanostructured systems for improved treatment and prevention of HIV diseaseThe application of nanotechnology in medicine: treatment and diagnosticsFlow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions
P2860
Q28821119-3353EB0A-2E80-417B-8EF1-D3F446AA48B4Q30372133-E76F29B7-DC78-48E7-A3E5-0E351CAEBFA7Q34571360-FA765B92-8770-4520-B74D-CA8F55028393Q35668556-78A48FA6-8975-4521-8F65-2AF9AD2CFE69Q36919868-A5E6D9E3-ABF7-4358-B102-74E855EE4586Q36934918-F765BFDE-F428-49F7-BAC0-D5C4926D4350Q38170326-A4A61595-34BF-4FAD-B71B-7CFF7C1036A0Q38365556-607B4CF7-C5C3-4339-859B-48DA79AC7DB5Q38495022-3151CA53-378C-401B-B09A-95274DC4AAC6Q38687039-A3ACBA6D-4AF8-4C09-8521-B5429A0A559BQ38750666-ECCAE926-DD40-4D7A-8D70-DD3BDE9CFB8DQ41219268-7277F731-BCDE-466F-9DB8-F5AAD6B413C9Q42238071-2BB8A947-82BC-488B-9C35-38FAE2A52290Q47112878-C6C9FA39-7256-4617-9885-9440E446F6B8Q47817799-981E8710-6203-4DDE-B744-81BED7C53CA0Q48022850-4E24AC74-065E-45E0-8B41-5BD7890B2564Q48093677-830A640D-E4AA-4083-A4C8-839A91B3563DQ48337638-B09C3AA6-B434-4210-BE5F-FC79C84D19F2Q51739696-FCDD26C4-ECB4-4B3F-8525-671CCEE7C795Q53555823-57C34F75-473E-4FCB-B7C0-39974D5E4A84Q56992437-98A88EDA-D70D-4856-A568-7934372F9AD0Q57616669-7107D080-8DDB-4771-8566-2E2AB6545F48Q58073502-26E498E5-01DC-4A31-91E1-9FB96F668D1A
P2860
Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Antiretroviral solid drug nano ...... in vitro-in vivo correlation.
@en
Antiretroviral solid drug nano ...... in vitro-in vivo correlation.
@nl
type
label
Antiretroviral solid drug nano ...... in vitro-in vivo correlation.
@en
Antiretroviral solid drug nano ...... in vitro-in vivo correlation.
@nl
prefLabel
Antiretroviral solid drug nano ...... in vitro-in vivo correlation.
@en
Antiretroviral solid drug nano ...... in vitro-in vivo correlation.
@nl
P2093
P2860
P50
P356
P1476
Antiretroviral solid drug nano ...... in vitro-in vivo correlation.
@en
P2093
Alessandro Schipani
Alison J Foster
Darren Smith
James Long
Philip Martin
Phill Roberts
Saye H Khoo
P2860
P304
P356
10.1002/ADHM.201300280
P50
P577
2013-09-01T00:00:00Z